Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2014

View Archived Issues

Large-scale in vitro production of human insulin-producing pancreatic beta cells from stem cells

Safety and clinical efficacy of CreaVax-RA tested in patients with RA

Monoclonal antibody therapy evaluated in models of neuropathic pain

Cystic Fibrosis Foundation Therapeutics forms research collaboration with Shire

New companies join Early Diagnosis Consortium on biomarkers for early cancer detection

Roche initiates phase I trial of CD40 agonist RO-7009789 in combination with PD-L1 ligand

X-Chem and Alexion to discover novel candidates to treat severe, ultra-rare disorders

OncoTherapy Science discloses IMP-3-based cancer vaccines

Apogee receives grant to begin trial of ABC-294640 in lymphoma

ImmunID authorized to initiate trial of ImmunTraCkeR to predict response to ipilimumab

New biotech company: Northern Biologics

Great Basin initiates clinical trial for Staph ID/R diagnostic test

Complera combination tablet for HIV-1 launched in Japan

AstraZeneca patents novel SERDs

Novartis patents report new BRD2, 3 and 4 inhibitors

New hedgehog signaling inhibitors designed at Redx Pharma

Safety data presented for onartuzumab plus bevacizumab combination therapy in recurrent glioblastoma

FDA approves Fluzone intradermal quadrivalent influenza vaccine

New formulation of Salagen launched in Japan for treating dry mouth

ChemoCentryx reports topline data from phase II trial of CCX-140

Batu Biologics files IND application for cancer vaccine targeting tumor endothelium

New IND application for Etuary submitted in China

Genentech submits NDA for cobimetinib in combination with vemurafenib for advanced melanoma

Novel selective Mcl-1 inhibitors show efficacy against hematological malignancies

FDA approves Cyramza for metastatic NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...